PHASQ — PhaseBio Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$3.73m
- $10.83m
Annual income statement for PhaseBio Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.668 | 2.36 | 0.32 | 10.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 8.54 | 20.3 | 42.1 | 85.2 | 118 |
| Operating Profit | -8.54 | -19.6 | -39.7 | -84.9 | -107 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.2 | -23.8 | -39.2 | -98.6 | -129 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.2 | -23.8 | -39.2 | -98.6 | -131 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -10.2 | -23.8 | -39.2 | -98.6 | -131 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.2 | -23.8 | -39.2 | -98.6 | -131 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.523 | -0.973 | -1.43 | -3.39 | -2.98 |
| Dividends per Share |